Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Stopped early

Conditions studied: Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular

In brief

The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, participant-level data longitudinally in participants diagnosed with various subtypes of non-Hodgkin lymphoma (NHL).

Key facts

Study ID

NCT04982471

Run by

Celgene

People needed

36

Starts

2021-11-03

Expected to finish

2023-08-03

Last updated by the study team

2025-03-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be ≥18 years of age at the time of consent
• Must be able to provide written informed consent personally or by legally authorized representative
• Must have 1 of the following histologically confirmed Non-Hodgkin Lymphoma (NHL) subtypes:
• Diffuse large B-cell lymphoma (DLBCL), NOS; or DLBCL high-grade lymphoma, not otherwise specified (NOS); or DLBCL high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (double/triple-hit lymphoma)
• Epstein-Barr virus-positive or composite DLBCL are allowed
• Follicular lymphoma (FL)
• Must have been previously treated with ≥ 1 prior systemic therapy (e.g., chemotherapy, immunotherapy, or chemoimmunotherapy)
• For first relapsed/refractory (R/R) DLBCL cohort, participant must have confirmed R/R disease within 90 days prior to study enrollment and must intend to initiate 2L systemic treatment
• For first R/R FL cohort, participant must have confirmed R/R disease (grade 1 to 3B or transformed) within 90 days prior to study enrollment and must intend to initiate 2L systemic treatment
• Participant must be willing and able to complete enrollment and follow-up health-related quality of life (HRQoL) and social support instruments
• Participants volunteering for the Tissue Sub-Study must consent for use of their blood/tumor biopsies, which were collected as per standard of care, for exploratory analyses

You may not qualify if…

• Participant whose prior start and end date of DLBCL or FL treatment, and prior treatment received, including chemotherapy, radiation, surgery (not including excisional biopsies), and other anticancer therapy, are unknown
• Participant who has any other active malignancy (non-DLBCL or non-FL) for which the participant is receiving treatment at the time of enrollment or any other former malignancy that was diagnosed within 6 months prior to Registry enrollment (with the exception of non-melanoma skin cancer)
• Currently enrolled in any interventional clinical trial where the participant is being treated with an investigational product that cannot be identified

Where it is running

• Local Institution - 105 — Hot Springs, Arkansas, United States
• Rocky Mountain Cancer Centers (Boulder) - USOR — Boulder, Colorado, United States
• Woodlands Medical Specialists, PA — Pensacola, Florida, United States
• Local Institution - 169 — Pensacola, Florida, United States
• Bond Clinic, P.A. — Winter Haven, Florida, United States
• Local Institution - 121 — Winter Haven, Florida, United States
• Harbin Clinic — Rome, Georgia, United States
• Local Institution - 112 — Savannah, Georgia, United States
• Summit Cancer Care, PC — Savannah, Georgia, United States
• Local Institution - 127 — Urbana, Illinois, United States
• Cotton O'Neil Clinical Research, Hematology and Oncology — Topeka, Kansas, United States
• Local Institution - 133 — Topeka, Kansas, United States
• Local Institution - 134 — Lewiston, Maine, United States
• Local Institution - 106 — Bethesda, Maryland, United States
• Regional Cancer Care Associates — Bethesda, Maryland, United States
• Local Institution - 139 — Chevy Chase, Maryland, United States
• Local Institution - 101 — Cumberland, Maryland, United States
• UPMC Western Maryland Corporation — Cumberland, Maryland, United States
• Local Institution - 130 — Hyannis, Massachusetts, United States
• Local Institution - 110 — Saint Louis Park, Minnesota, United States
• Oncology Research, HealthPartners Institute — Saint Louis Park, Minnesota, United States
• Local Institution - 119 — Joplin, Missouri, United States
• Local Institution - 108 — Lincoln, Nebraska, United States
• Local Institution - 162 — Reno, Nevada, United States
• Genesis Cancer Center — Hot Springs, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.